House to mark up bill tar­get­ing Chi­nese biotech and ge­nomics com­pa­nies

The House Over­sight Com­mit­tee will mark up a far-reach­ing bill on May 15 that, if passed, could force many US bio­phar­ma com­pa­nies to cut ties with WuXi and sev­er­al oth­er Chi­nese life sci­ences con­trac­tors, a con­gres­sion­al aide con­firmed to End­points News.

The markup sig­nals build­ing, bi­par­ti­san mo­men­tum on the close­ly-watched bill that could have wide-rang­ing im­pli­ca­tions for dozens of com­pa­nies. A sim­i­lar bill passed out of the Home­land Se­cu­ri­ty and Gov­ern­men­tal Af­fairs Com­mit­tee ear­li­er this spring.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER